Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Fruquintinib by Takeda Pharmaceutical for Rectal Cancer: Likelihood of Approval
Fruquintinib is under clinical development by Takeda Pharmaceutical and currently in Phase I for Rectal Cancer. According to GlobalData, Phase...
Fruquintinib by Takeda Pharmaceutical for Endometrial Cancer: Likelihood of Approval
Fruquintinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...
Fruquintinib by Takeda Pharmaceutical for Solid Tumor: Likelihood of Approval
Fruquintinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Fruquintinib by Takeda Pharmaceutical for Angiosarcoma: Likelihood of Approval
Fruquintinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Angiosarcoma. According to GlobalData, Phase II...
Fruquintinib by Takeda Pharmaceutical for Metastatic Pancreatic Cancer: Likelihood of Approval
Fruquintinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData,...
Fruquintinib by Takeda Pharmaceutical for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Fruquintinib is under clinical development by Takeda Pharmaceutical and currently in Phase I for Human Epidermal Growth Factor Receptor 2...
Fruquintinib by Takeda Pharmaceutical for Soft Tissue Sarcoma: Likelihood of Approval
Fruquintinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData,...
Fruquintinib by Takeda Pharmaceutical for Angiosarcoma: Likelihood of Approval
Fruquintinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Angiosarcoma. According to GlobalData, Phase II...
Fruquintinib by Takeda Pharmaceutical for Metastatic Pancreatic Cancer: Likelihood of Approval
Fruquintinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData,...